Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Active:	Yes
Cancer Type:	Unknown Primary Uterine Cancer	NCT ID:	NCT05611931
Trial Phases:	Phase III	Protocol IDs:	XPORT-EC-042 (primary) NCI-2023-01755 ENGOT-EN20 GOG-3083
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Karyopharm Therapeutics Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT05611931

Summary

The purpose of this study is to evaluate the efficacy and safety of selinexor as a
maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have
achieved a partial response (PR) or complete response (CR) (per Response Evaluation
Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks
of platinum-based therapy. A total of 220 participants will be enrolled in the study and
randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.

Treatment Sites in Georgia

Northeast Georgia Medical Center - Gainesville
NGMC-Gainesville
Wisteria Building Suite 420
200 South Enota
Gainesville, GA 30501
770-219-8822
www.nghs.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.